Mathias Orban

Cardiologist and Intensive Care Specialist

[Mathias Orban @maorban]

News from #TRILUMINATE @JACCJournals @JoaoLCavalcante @psorajja How to execute advanced imaging substudy in randomized trial. Right heart reverse remodeling after TR clip. Editorial by @nickaram @PhilippLurz @j_hausleiter @stolz_l https://t.co/Kbe2tij56f
https://t.co/uZ9doZHZHM

[Victor Dayan @VictorDayan1]

The power of randomization in open blinded trials….it gets almost 30% of patients with AS who were asymptomatic for years to be symptomatic in less than 6 months after randomization !!!! This is EARLY TAVR. https://t.co/kPpL08zv6k

[Kami Pekayvaz @KPekayvaz]

Unexpected new insights into the role of antibodies in mediating venous thrombosis by Konstantin Stark’s Lab. Definitely worth a read!

[Mathias Orban @maorban]

@hahn_rt @DonalErwan @ESCardioNews @escardio Congrats to the authors. Now its up to TRICI-HF trial from @j_hausleiter @stolz_l @LMU_Uniklinikum to show maybe an effect on hard clinical endpoints.

[Mathias Orban @maorban]

@nickaram @PCRonline I have not read it yet, but does this study help to explain why MITRA-FR did not improve any outcomes?

[Giuseppe Biondi-Zoccai @gbiondizoccai]

Highlights of The Evolving Concept of Secondary Mitral Regurgitation Phenotypes: Lessons From the M-TEER Trials, just published in JACC: Cardiovascular Imaging:
1. Secondary mitral regurgitation (SMR) is a heterogeneous disease entity presenting with different clinical phenotypes
2. Differentiation of SMR phenotypes (aSMR vs vSMR) and their subentities might facilitate our understanding of treatment response to medial and interventional SMR treatment
3. Further studies are needed to further improve our understanding of the disease and optimize treatment of SMR
https://t.co/icxnnHZMmG @JACCJournals

[Holger Thiele @thiele_holger]

@GreggWStone @JasonKatzMD @seanvandiepen @CHassager @benhibbertMDPhD just to let you think. Any explanation for the shortest ICU time ever in a #AMICS RCT in Control? Preemptive decision for end of life???

[NEJM @NEJM]

Patients with evidence of microplastics and nanoplastics in carotid artery plaque, as compared with patients without, had a greater risk of adverse cardiovascular events at 34 months of follow-up. Read the full article: https://t.co/BUsdzHMcdb

[Davide Capodanno @DFCapodanno]

My post-coronary angiography patient talk revisited after ORBITA and ORBITA-2: "Dear patient with chest pain and no pills, if I fix this artery you won't live one day longer, but you may have less angina, or you can take one or more pills and achieve more or less the same".

[Mathias Orban @maorban]

Every question answered for transcatheter mitral repair with COAPT Post Approval Study by @kashishgoelmd @JACCJournals? Check out the Editorial from @Cardio_LMU @LMU_Uniklinikum @j_hausleiter where we outline future directions for valvular #heartfailure https://t.co/NKSy5M0Tf9

[Mathias Orban @maorban]

@kashishgoelmd Congrats to the authors. @j_hausleiter @LMU_Uniklinikum @Cardio_LMU and I discuss the results and give future directions for the field of transcatheter mitral repair. What are open questions for #TEER? Or is everything clear now? https://t.co/NKSy5M0Tf9

[Kashish Goel @kashishgoelmd]

The COAPT Post Approval Study is out in @JACCJournals today!

Real world data on 5000 SMR patients treated with MitraClip at 406 sites showed that it was safe and effective.
Free download available at this link for next 50 days: https://t.co/YsS6EmCBoL

[Karl-Patrik Kresoja @KP_Kresoja]

In an ideal world every 💊 we prescribe prevents an event #NNT1

Not there yet, but we may have come closer

Now in @eBioMedicine how to identify optimal responders to spironolactone in HFpEF a🧵
@PhilippLurz @m_unterhuber @thiele_holger
https://t.co/ZqvXcqNOUN

[Mathias Orban @maorban]

@KP_Kresoja Results will be the same for every mechanical support trial. Congrats to @thiele_holger and colleagues for executing the trial

[Karl-Patrik Kresoja @KP_Kresoja]

Now that we have seen that #ECLS-SHOCK is neutral #ESCCongress what is going to be your get to with cardiogenic shock patients? 🏥
@thiele_holger @feistritzerH_J @JaninePoss @DGK_org @YoungDgk @MarcVorpahl @GFurnau @KardiologieHH @kp_rommel @Steph_Achenbach @Drroxmehran

[Univ.-Prof. Dr. Ralph Stephan von Bardeleben @vonBardelebenRS]

Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic #TRILUMINATE Trial

Ralph Stephan von Bardeleben, Philipp Lurz, Paul Sorajja, … on behalf of the Trial Investigators

online today, Aug 2023: https://t.co/QzHipWxeKK

[Mathias Orban @maorban]

Transcatheter Therapy for Tricuspid Regurgitation — First Act | NEJM https://t.co/zSEBETji7g

[Mathias Orban @maorban]

https://t.co/095JXT4x36

https://t.co/IOIPQDtIvY

https://t.co/FSbszOo7QW

@NEJM @PhilippLurz @vonBardelebenRS @hahn_rt

[Mathias Orban @maorban]

Prof Massberg @Cardio_LMU + I had the privilege to write Editorial on #TRILUMINATE pivotal trial by @psorajja. I guess we all hoped for reduction of 🏥 ( maybe ☠️), but remember: This is the #first #randomized trial ever for severe isolated #TR! T-TEER is safe and improves QoL

[NEJM @NEJM]

Editorial: Transcatheter Therapy for Tricuspid Regurgitation — First Act https://t.co/WaIeLob7me